(Q37788586)

23 August 2017

title

Significance of hyponatremia in heart failure (English)

1 reference

23 August 2017

0 references

1 reference

Christopher M O'Connor

series ordinal

4

object named as

Christopher M O'Connor

1 reference

23 August 2017

Luca Bettari

1

1 reference

23 August 2017

Mona Fiuzat

series ordinal

2

1 reference

23 August 2017

Gary M Felker

series ordinal

3

1 reference

23 August 2017

publication date

1 January 2012

1 reference

23 August 2017

published in

Heart Failure Reviews

1 reference

23 August 2017

volume

17

1 reference

23 August 2017

issue

1

1 reference

23 August 2017

page(s)

17-26

1 reference

https://scigraph.springernature.com/pub.10.1007/s10741-010-9193-3

23 August 2017

exact match

0 references

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9193-3

The current cost of heart failure to the National Health Service in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9193-3

Heart Disease and Stroke Statistics--2008 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9193-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9193-3

Hyponatremia in patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9193-3

Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9193-3

Hyponatremia and heart failure--pathophysiology and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9193-3

Predicting death due to progressive heart failure in patients with mild-to-moderate chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9193-3

Hyponatremia in congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9193-3

Hyponatremia and vasopressin antagonism in congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9193-3

Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9193-3

Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9193-3

Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9193-3

A prognostic index to predict long-term mortality in patients with mild to moderate chronic heart failure stabilised on angiotensin converting enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9193-3

The Seattle Heart Failure Model: prediction of survival in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9193-3

Risk stratification after hospitalization for decompensated heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9193-3

Triage after hospitalization with advanced heart failure: the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) risk model and discharge score

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9193-3

Hormones and hemodynamics in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9193-3

Angiotensin II directly stimulates sodium transport in rabbit proximal convoluted tubules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9193-3

Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9193-3

Vasopressin: a new target for the treatment of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9193-3

Water and sodium regulation in chronic heart failure: the role of natriuretic peptides and vasopressin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9193-3

Upregulation of aquaporin-2 water channel expression in chronic heart failure rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9193-3

Both V(1A) and V(1B) vasopressin receptors deficiency result in impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9193-3

Congestive heart failure: potential role of arginine vasopressin antagonists in the therapy of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9193-3

Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9193-3

Hyponatremia treatment guidelines 2007: expert panel recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9193-3

The role of V2 vasopressin antagonists in hyponatremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9193-3

Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9193-3

Vasopressin receptor antagonism--a therapeutic option in heart failure and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9193-3

The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9193-3

Vasopressin: a therapeutic target in congestive heart failure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9193-3

Vaptans and the treatment of water-retaining disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9193-3

Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9193-3

Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9193-3

Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9193-3

Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9193-3

Vasopressin antagonism in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9193-3

Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9193-3

Characterization and Prognostic Value of Persistent Hyponatremia in Patients With Severe Heart Failure in the ESCAPE Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9193-3

Physiology and pathophysiology of renal aquaporins.

21 January 2018

1 reference

12 December 2020

Temporal Trends in Survival and Hospitalizations in Outpatients With Chronic Systolic Heart Failure in 1995 and 1999

1 reference

12 December 2020

V2-vasopressin receptor antagonists-mechanism of effect and clinical implications in hyponatraemia

1 reference

12 December 2020

Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation

1 reference

12 December 2020

Vasopressin and angiotensin II receptors in rat aortic smooth muscle cells in culture

1 reference

12 December 2020

Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure

1 reference

12 December 2020

Rationale and design of the treatment of hyponatremia based on lixivaptan in NYHA class III/IV cardiac patient evaluation (THE BALANCE) study

1 reference

12 December 2020

Pathogenesis and diagnosis of hyponatremia

1 reference

12 December 2020

Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia

1 reference

12 December 2020

Vasopressin increases cytosolic free [Ca2+] in the neonatal rat cardiomyocyte. Evidence for V1 subtype receptors

1 reference

12 December 2020

Increased plasma arginine vasopressin levels in patients with congestive heart failure

1 reference

12 December 2020

Hyponatremia: a prospective analysis of its epidemiology and the pathogenetic role of vasopressin

1 reference

12 December 2020

The MUSIC Risk score: a simple method for predicting mortality in ambulatory patients with chronic heart failure.

1 reference

12 December 2020

The role of vasopressin in congestive heart failure

1 reference

12 December 2020

Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients

1 reference

12 December 2020

Plasma ADH level in patients with chronic congestive heart failure

1 reference

12 December 2020

Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity

1 reference

12 December 2020

Readmission after hospitalization for congestive heart failure among Medicare beneficiaries.

1 reference

12 December 2020

Neural control of renal function in edema-forming states

1 reference

12 December 2020

Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V(1A) receptor

1 reference

12 December 2020

Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD)

1 reference

12 December 2020

10.1007/S10741-010-9193-3

Identifiers

DOI

1 reference

23 August 2017

1 reference